Intraprocedural thrombotic events

WikiDoc Resources for Intraprocedural thrombotic events
Articles
Most recent articles on Intraprocedural thrombotic events Most cited articles on Intraprocedural thrombotic events Review articles on Intraprocedural thrombotic events Articles on Intraprocedural thrombotic events in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Intraprocedural thrombotic events Images of Intraprocedural thrombotic events Photos of Intraprocedural thrombotic events Podcasts & MP3s on Intraprocedural thrombotic events Videos on Intraprocedural thrombotic events
Evidence Based Medicine
Cochrane Collaboration on Intraprocedural thrombotic events Bandolier on Intraprocedural thrombotic events TRIP on Intraprocedural thrombotic events
Clinical Trials
Ongoing Trials on Intraprocedural thrombotic events at Clinical Trials.gov Trial results on Intraprocedural thrombotic events Clinical Trials on Intraprocedural thrombotic events at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Intraprocedural thrombotic events NICE Guidance on Intraprocedural thrombotic events NHS PRODIGY Guidance FDA on Intraprocedural thrombotic events CDC on Intraprocedural thrombotic events
Books
Books on Intraprocedural thrombotic events
News
Intraprocedural thrombotic events in the news Be alerted to news on Intraprocedural thrombotic events News trends on Intraprocedural thrombotic events
Commentary
Blogs on Intraprocedural thrombotic events
Definitions
Definitions of Intraprocedural thrombotic events
Patient Resources / Community
Patient resources on Intraprocedural thrombotic events Discussion groups on Intraprocedural thrombotic events Patient Handouts on Intraprocedural thrombotic events Directions to Hospitals Treating Intraprocedural thrombotic events Risk calculators and risk factors for Intraprocedural thrombotic events
Healthcare Provider Resources
Symptoms of Intraprocedural thrombotic events Causes & Risk Factors for Intraprocedural thrombotic events Diagnostic studies for Intraprocedural thrombotic events Treatment of Intraprocedural thrombotic events
Continuing Medical Education (CME)
CME Programs on Intraprocedural thrombotic events
International
Intraprocedural thrombotic events en Espanol Intraprocedural thrombotic events en Francais
Business
Intraprocedural thrombotic events in the Marketplace Patents on Intraprocedural thrombotic events
Experimental / Informatics
List of terms related to Intraprocedural thrombotic events

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: IPTE

Overview

Intraprocedural thrombotic events (IPTE) are a rare group of acute ischemic complications that occur during percutaneous coronary interventions (PCI). Although by definition IPTE should occur before the end of the PCI procedure; it can come about before or after stent-placement during PCI. In contrast to other complications that might occur before or after PCI, IPTE has recently been recognized as a special category of complications that include distinctive risk factors and associated patient and procedural characteristics. Most importantly, IPTE comprises a unique predictor of periprocedural and postprocedural adverse clinical outcomes and overall patient prognosis. As such, the emergent objective understanding of IPTE and its reproducible effects are expected to render IPTE as a clinical end-point in PCI rather than a mere intraprocedural observation.

Classification

• New thrombus formation
• Increased thrombus size
• Abrupt vessel closure
• No reflow|No reflow phenomenon]] (new TIMI flow grade 0 or 1)
• Slow reflow phenomenon (new TIMI flow grade 2)
• Distal embolization
• Loss of side branch
• Intraprocedural stent thrombosis (IPST)

Epidemiology and Demographics

• The overall rate of IPTE is currently estimated to be 3.5-11.4% of all PCI procedures.
• In 2012, McEntegart et al. performed frame-by-frame analysis for 3,428 patients with [[NSTEMI}non-ST elevation acute coronary syndrome]] (NSTEACS) previously enrolled in the ACUITY trial (Acute Catherterization and Urgent Intervention Triage Strategy). The total incidence of IPTE was 3.5% with varying rates of occurrence among specific etiologies of IPTE. 89.3% of all IPTE occurred at the level of a main branch.

• Similarly in 2012, Pride et al. evaluated 1,452 high-risk patients with NSTTEAS enrolled in the EARLY ACS trial (Early Glycoprotein IIb/IIIa in Non-ST-Segment Elevation Acute Coronary Syndrome ) who underwent angiographic assessment. Incidence of IPTE was 11.4%.

• In contrast to McEntegart, the study by Pride et al. included high-risk patients only. High-risk criteria were defined by the authors as having at least two of the following: Ischemic changes on electrocardiography (ECG), elevated cardiac enzyme, advanced age ≥ 60 years or age between 50-59 with documented coronary artery disease, cerebrovascular disease, or peripheral vascular disease. It is uncertain whether the inclusion criteria played a role in the increase of IPTE rates in the study as compared to McEntegart’s findings.

Complications and Prognosis

• Patients who experience intraprocedural complications are at higher risk of postprocedural 30-day and one year morbidity and mortality. Notably, the number of intraprocedural complications also correlates with the severity of periprocedural outcomes.

• Shown below is a table demonstrating the significant difference in rates of adverse cardiac events in patients with and without IPTE.

Adverse Cardiac Events	In-hospital	30-day	1-year
Patients with IPTE	25.6%	30.6%	37%
Patients without IPTE	6.3%	9.3%	20.5%

• The risk of death or myocardial infarction (MI), especially Q-wave MI, within 30 days following PCI is four times higher in patients who experience IPTE, even after adjusting for other possible confounding risk factors.

Shown below is an image depicting the risk of death or MI in relation with the number of IPTE.

• The rates of other cardiac thrombotic and non-thrombotic complications are also significantly increased following IPTE in both the periprocedural time frame and after 1 year post-PCI. Associated complications include stent thrombosis, unplanned revascularization, target vessel revascularization (TVR), coronary artery bypass graft (CABG), and non-CABG major bleeding.

• After evaluating angiographic results post-PCI in patients with vs. without IPTE, IPTE was found to be more significantly associated with a worse post-PCI TIMI flow grade and myocardial perfusion grade. Interestingly, IPTE was found to be a more important correlate with 30-day death and MI than pre-PCI elevation of cardiac enzymes in the NSTEACS patient population. However, the number of patients reported by Pride and colleagues regarding this result was very small; the exact etiology for such findings are yet to be revealed as to whether they are incidental or in fact consequences of prior unrelated cardiac events in these patients.

• Because IPTE sometimes includes adverse outcomes not accounted for in conventional PCI assessments, the addition of IPTE observations in PCI to already known risk factors of adverse outcome seems to provide a more comprehensive and more realistic prognostic impression for patients undergoing PCI.

References

Template:WikiDoc Sources